Kidney-pancreas (KP) transplantation has been shown to improve left ventricular (LV) geometry and func tion 6-24 months after the procedure, yet whether these improvements are sustained in long-term survivors has not been demonstrated. This study examined whether early improvements in LV geometry and function were sustained 3-5 years after KP transplantation. Left ventricular function and geometry were prospectively evaluated prior to, and at 1,2, and 3-5 years posttransplant using two-dimensional, M-mode, echocardiogra phy with Doppler interrogation in the parasternal and apical views. The sample included 21 KP and a comparison group of 12 diabetic kidney-alone (KA) recipients. Long-term (3-5 years) data were obtained for KP recipients only. Although KA recipients had a longer duration of dialysis and worse diastolic function pretransplant, the groups were similar on other baseline measures. KA recipients experienced minimal im provements while KP recipients had significant improvements in cardiac function and geometry, both in terms of mean values and the percentage of KP recipients who experienced normalization posttransplant (p < 0.05). KP recipient improvements were also sustained at 3-5 years posttransplant on three of five mea sures, with 75% of long-term KP recipients achieving normal LV mass posttransplant compared with 31% pretransplant. Data indicate that significant impairments in cardiac geometry and function occur in diabetic KA and KP recipients. Though both groups experienced early improvements posttransplant, KP recipients achieved more dramatic and clinically significant improvements at 1,2, and 3-5 years posttransplant. Addi tional studies are needed to examine the relevance of these findings with regard to the cardiac morbidity and mortality of these patients.
INTRODUCTION
Diabetes mellitus, the most common cause of endstage renal disease (ESRD) in the US, is associated with significant cardiac morbidity and mortality (21) . Dia betic cardiomyopathy, in the absence of clinically rele vant macrovascular disease, is a known complication of type I disease (16) . Animal and clinical studies, autop sies, and epidemiological data document the incidence, prevalence, and characteristics of the disorder (2, 8, 11) .
The etiology of diabetic cardiomyopathy, however, re mains unclear. Multiple mechanisms have been pro posed, including cardiac autonomic denervation, micro vascular disease, and altered cardiac myocyte fuel supply and utilization (2, 18) . Diabetic cardiomyopathy occurs within the context of comorbid conditions that influence its clinical presentation and treatment. Cardiac dysautonomia results in decreased heart rate variability for patients with diabetes (13, 16) . Although diastolic impairment is the hallmark of the disease, car diac imaging reveals subclinical left ventricular (LV) dysfunction related to cardiac adrenergic denervation in some patients (1) . Defects in vagal modulation of heart rate occur relatively early in the course of the disease, while adrenergic impairment is a late and less frequent manifestation of the disorder (16) .
The contribution of microvascular disease to diabetic cardiomyopathy remains controversial. Findings from several studies suggest that microaneurysms of myocar dial arterioles and thickened intimal basement mem branes in diabetic patients are common, yet autopsy studies have not supported these findings (5, 7, 19) . genesis of the disorder (2, 18) . Excess free fatty acid sup ply and uptake are thought to inhibit glucose oxidation and result in severe structural changes in the cardiac muscle cell (18) . In addition, animal models suggest that defects in calcium ion transport, myocardial contractile proteins, and collagen formation may contribute to car diac myocyte morphologic and physiologic changes (10, 11, 17) .
Regardless of the etiology, appropriate and effective therapies for diabetic cardiomyopathy are needed (2) .
Glycemic control has been advocated as the most effica cious approach to treat the disorder (2) . While insulin therapy improves cardiomyopathy in animal models, it is unclear whether this strategy can improve cardiomy opathy in humans (6, 20) . Despite improved glycemic control with intensive insulin therapy in humans, ele vated HbAlc levels and hyperinsulinemia persist. In contrast, successful kidney-pancreas (KP) transplanta tion produces euglycemia, relatively normal renal func tion, and has been associated with improved diastolic and systolic function and left ventricular geometry in diabetic uremic patients 1 year postprocedure (9) . Al though these findings are promising, it is unclear whether early improvements are sustained. The objec tive of this study, therefore, was to determine whether the improvements in LV geometry and function ob served using echocardiography at 1 year posttransplant were sustained 3-5 years (long term) following com bined KP transplant.
MATERIALS AND METHODS

Design
This report reflects the results of a longitudinal, pro spective cohort study that examined the short-term 
Patients
To assure comparability between the two groups, all patients admitted to the study met the same inclusion and exclusion criteria. Patients were greater than 18 years of age, had a stimulated C-peptide of <0.05 ng/dl, and were eligible for the KP procedure (even if they were evaluated for KA transplantation). Patients were excluded from the study if they were deemed ineligible for KP transplantation during the pretransplant evalua tion, were pregnant, or had clinically significant uncor rected ischemic heart disease (diagnosed by a cardiolo gist).
Data Collection
At pretransplant baseline and yearly intervals trans within the study is provided in Table 1 .
Statistical Analysis
For both groups of patients pre-and posttransplant differences in longitudinal echocardiographic outcomes 
RESULTS
Patient Characteristics
Baseline demographic data for the two groups were similar with the exception that KA recipients had a sig nificantly longer dialysis history and most KP recipients were female while most KA recipients were male ( Table   2 ). Two KA recipients had greater than 5 years of dial ysis therapy (67 and 72 months) prior to transplant.
When these patients were excluded from the statistical analysis, the durations of dialysis therapy for the two groups were similar (10.4 ±9.6 and 8.6 ±8.9, respec tively). KP and KA recipient baseline echocardiograms were not significantly different.
Outcomes KP recipients experienced abnormal LV geometry as indicated by increased PWT, IVST, and mass at base line, while mean diastolic and systolic function (EA peak and ShFx, respectively) were within the established limits of normal (Table 3) Similar findings occurred with regard to long-term improvements in these patients. Table 4 depicts the changes in the percentage of KP and KA recipients whose LV structure and function normalized at each Values reported are means ± SEM. ShFx: shortening fraction; IVST: interventricular septal thickness; PWT: posterior wall thickness; Mass: left ventricular mass. *Reflects p < 0.05 using one-way analysis of variance with preplanned comparisons. Values reported reflect percent of tests that were within normal limits. Missing data were present for some KP and KA recipients; however, values were calculated for patients with data at both measurement periods. *Reflects p < 0.05 using chi-square analysis to assess within-group changes. tReflects p < 0.10 using chi-square analysis to assess within-group changes.
posttransplant measurement point (1, 2, and 3-5 years).
A substantial percentage of KP recipients experienced normalization of LV structure and function at the 1 -year period and improvements were sustained at the 3-5-year anniversary.
DISCUSSION
Cardiomyopathy is a frequent complication of type I diabetes mellitus (8) . Framingham study findings docu mented significant LV hypertrophy in persons with dia betes, in the absence of clinical disease (11 This improvement is noteworthy because diastolic dys function is the hallmark of diabetic cardiomyopathy.
Our findings provide evidence that cardiomyopathy may be reversible in some patients following KP transplanta tion. Improvements occurred despite the fact that most KP recipients were diabetic women who, according to findings from the Framingham study, have 5.8-fold in creased risk of heart failure and more severe heart fail ure when compared to persons who are not diabetic (14) . 
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